These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 11409152

  • 1. Disease modifying antirheumatic drugs: longterm safety issues.
    Capell HA.
    J Rheumatol Suppl; 2001 Jun; 62():10-5. PubMed ID: 11409152
    [Abstract] [Full Text] [Related]

  • 2. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 3. Longterm maintenance therapy with disease modifying antirheumatic drugs.
    Capell H.
    J Rheumatol Suppl; 2002 Nov; 66():38-43. PubMed ID: 12435167
    [Abstract] [Full Text] [Related]

  • 4. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG.
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [Abstract] [Full Text] [Related]

  • 5. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE.
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [Abstract] [Full Text] [Related]

  • 6. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

  • 7. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G, Aviña-Zubieta JA, Russell AS, Suarez-Almazor ME.
    J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
    [Abstract] [Full Text] [Related]

  • 8. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T, Pincus T.
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [Abstract] [Full Text] [Related]

  • 9. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
    Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Leirisalo-Repo M.
    Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
    [Abstract] [Full Text] [Related]

  • 10. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P.
    J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
    [Abstract] [Full Text] [Related]

  • 11. [Combination therapy in rheumatoid arthritis].
    Johnsen V, Førre Ø, Haga HJ, Kvien TK, Mikkelsen K, Nordvåg BY, Rødevand E.
    Tidsskr Nor Laegeforen; 2003 May 29; 123(11):1511-3. PubMed ID: 12822010
    [Abstract] [Full Text] [Related]

  • 12. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug 29; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 13. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA.
    J Rheumatol; 2002 Aug 29; 29(8):1639-45. PubMed ID: 12180722
    [Abstract] [Full Text] [Related]

  • 14. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.
    Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW.
    J Rheumatol; 2006 May 29; 33(5):854-61. PubMed ID: 16541481
    [Abstract] [Full Text] [Related]

  • 15. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
    Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA.
    J Rheumatol; 2002 Feb 29; 29(2):261-6. PubMed ID: 11838843
    [Abstract] [Full Text] [Related]

  • 16. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.
    Blomqvist P, Feltelius N, Ekbom A, Klareskog L.
    J Rheumatol; 2000 May 29; 27(5):1171-7. PubMed ID: 10813283
    [Abstract] [Full Text] [Related]

  • 17. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
    Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, Yamanaka M, Yamanaka H, Kamatani N.
    Pharmacogenet Genomics; 2007 Jun 29; 17(6):383-90. PubMed ID: 17502830
    [Abstract] [Full Text] [Related]

  • 18. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH, Whelton A.
    Semin Arthritis Rheum; 2000 Dec 29; 30(3):196-208. PubMed ID: 11124283
    [Abstract] [Full Text] [Related]

  • 19. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE.
    Arthritis Res Ther; 2006 Dec 29; 8(5):R151. PubMed ID: 16984661
    [Abstract] [Full Text] [Related]

  • 20. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Agarwal S, Zaman T, Handa R.
    Singapore Med J; 2009 Jul 29; 50(7):686-92. PubMed ID: 19644623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.